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Highlights 
 In vitro metabolic efficiency of Benzo[a]pyrene 
 MCL-5 and HepG2 cell lines gave significant genotoxiity after 4h and 24h treatments 
 CYP450 enzymes and  mEH in gentotoxicity and mutagenicity   
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ABSTRACT 
Benzo[a]pyrene (B[a]P) is a known genotoxin and carcinogen, yet its genotoxic response at low level exposure 
has not been determined. This study was conducted to examine the interplay of dose and metabolic capacity on 
genotoxicity of B[a]P . Investigating and better understanding the biological significance of low level chemical 
exposures will help improve human health risk assessments. The genotoxic and mutagenic effects of B[a]P 
were investigated using human cell lines (AHH-1, MCL-5, TK6 and HepG2) with differential expression of the 
CYP450 enzymes (CYP1A1, 1B1 and1A2 involved in B[a]P metabolism. MCL-5 and HepG2 cells showed 
detectable basal expression and activity of CYP1A1, 1B1 and 1A2 than AHH-1 which only show CYP1A1 
basal expression and activity. TK6 cells showed negligible expression levels of all three CYP450 enzymes.  In 
vitro micronucleus and HPRT assays were conducted to determine the effect of B[a]P on chromosome damage 
and point mutation induction. After 24h exposure, linear increases in micronucleus (MN) frequency were 
observed in all cell lines except TK6. After 4h exposure, only the metabolically competent cell lines MCL-5 
and HepG2 showed MN induction (with a threshold concentration at 25.5µM from MCL-5 cells) indicating the 
importance of exposure time for genotoxicity.  The HPRT assay also displayed linear increases in mutant 
frequency in MCL-5 cells, after 4h and 24h treatments. Mutation spectra analysis of MCL-5 and AHH-1 HPRT 
mutants revealed frequent B[a]P induced G to T transversion mutations (72% and 44% of induced mutations in 
MCL-5 and AHH-1 respectively). This study therefore demonstrates a key link between metabolic capability, 
B[a]P exposure time  and genotoxicity.  
Key words: Genotoxicity; Mutagenicity; Dose-response; Metabolic activation; Threshold; Micronucleus  assay; 
HPRT assay  
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1. Introduction 
Genotoxins are chemicals that induce DNA mutations that can lead to cancer. Mutation in genes 
essential to perform normal regulatory processes like controlled cell signalling, cell cycle checkpoints and 
apoptosis, can lead to cancer development [1]. Some genotoxic chemicals, when released into the environment, 
can remain intact for long periods of time and cause adverse effects. It is important to assess the genotoxic 
potential of such chemicals for a better understanding of their carcinogenicity in order to reduce the potential 
risk of human cancer and other diseases involving acquired mutations in the somatic cells.  
 The link between environmental chemical exposure and human disease was first recorded in 1775 with 
the discovery of chimney sweeper’s cancer (soot wart), a squamous cell carcinoma of the skin of the scrotum, 
which originated from the components of soot [2]. The first report of the induction of squamous cell papilloma 
on rabbit ears after repeated exposure of coal tar, was published in 1918 [3]. Kennaway, in 1930, found that 
tumours in mouse skin could be produced by pure 1, 2, 5, 6 dibenzanthracene [4]. Later on in 1932, Cook and 
colleagues successfully isolated polycyclic aromatic hydrocarbon, benzo[a]pyrene (PAH, B[a]P) from coal tar, 
a highly carcinogenic crystalline compound [5]. 
 B[a]P belongs to a family of chemicals that can act like dioxins, based on a common mechanism of 
toxic action. Like dioxin compounds, PAHs have biologic responses mediated via binding to the aryl 
hydrocarbon receptor (AhR) which is a specific high-affinity cellular reporter protein [6] despite PAHs being 
quite different structurally from dioxins. Due to their potential risk to humans and animals, the United States 
Environmental Protection Agency (US-EPA) has designated 126 PAHs as priorities for environmental concern 
and B[a]P is one which is frequently monitored in the environment. B[a]P is generated through the burning of 
fossils fuels or wood, vehicle exhaust emission, heat and power generation, industrial processes or oil 
contamination and is always found environmentally as a mixture with other PAHs as in cigarette smoke, 
charcoal-cooked food and industrial waste by-products [7, 8].  
Human environmental exposure to B[a]P mainly occurs through cigarette smoking and the ingestion of 
contaminated food and water [7], with significant concentrations found in Western diet such as in fried and 
grilled meats. Both environmental and dietary factors are associated with an increased risk of different organ 
cancers [9], autoimmune [10] and inflammatory diseases [11]. The daily intake of B[a]P in the average human 
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diet has been estimated to range from 120- 2800ng/day [12] and concentration of B[a]P in full flavoured 
cigarettes has also been reported to be about 10ng per cigarette [13, 14], which is equivalent to an intake of 
about 200ng/day for a pack-a-day cigarette smoker [15]. B[a]P is transported across the cell membrane by 
lipoproteins [16] and B[a]P's presence activates the Aryl hydrocarbon receptor (AhR), which in turn binds with 
AhR nuclear translocator (ARNT) and induces the expression of genes involved in B[a]P metabolism as well as 
other genes that are not related to B[a]P metabolism. Several other genes such as the cytochrome P450 genes 
CYP1A1, CYP1A2, and CYP1B1, and glutathione-S-transferase (GST) and UDP-glucuronosyltransferase (UGT-
1) are also induced via AhR-mediated pathways. Indeed, the relative expression of phase I and phase II 
enzymes determines the ratio of activation and detoxification of B[a]P. B[a]P is often first oxidized at the bay 
region by phase I CYP1A1 into B[a]P-7,8-epoxide, which through hydration by microsomal epoxide hydrolase 
(mEH) is metabolized to B[a]P-7,8-dihydrodiol (BPD). BPD serves as a substrate for a second CYP dependent 
oxidation reaction and generates the metabolite B[a]P-7,8-dihydrodiol-9,10-epoxide (BPDE) [17]. BPDE 
contains an epoxide ring within the bay region making it highly reactive with DNA in a time dependent 
manner.  
 The genotoxicity of most direct acting genotoxins is dependent on the dose and length of exposure 
whereby genotoxic effects are observed at or above a critical dose. These doses are referred to as threshold 
doses, below which no observable genotoxic effect is seen. Nowadays a threshold level is commonly used to 
determine or establish a safe limit of a chemical for human use but only when their mechanism of action is 
established and accepted by risk assessment agencies. This threshold limit is derived from a combination of 
dose-dependent responses, mathematical and statistical models, to cover any variability, and risk assessment 
procedures. Typically a threshold level is a value between a no observable effect level (NOEL) and lowest 
observable effect level (LOEL) [18] and can be confirmed by mathematical modelling [19]. The nature of the 
chemical, its interaction with the non-DNA targets, and cell protective mechanisms (detoxification, DNA 
repair, etc.) are the mechanistic factors that influence dose-dependent responses [19]. Therefore, it is important 
to consider these factors while assessing if thresholds exist for any genotoxins. These considerations become 
even more complex if the genotoxin involved is a pro-carcinogen that requires metabolic activation to initiate 
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genotoxicity. As compared to direct acting agents, little is known about the threshold doses of pro-carcinogenic 
agents and the critical factors controlling dose response relationships for genotoxicity.  
 Considering this, the aim of this study was to identify the dose responses at the low dose range of B[a]P 
and determine whether there is differential genotoxicity and mutagenicity of B[a]P in different human cell lines 
based on their metabolic capacity of phase I enzymes. The cell lines used in the present study were human 
lymphoblastoid cell lines AHH-1, MCL-5, TK6 and primary hepatoblastoma cell line HepG2, known to have 
differential expression of phase I CYP450 enzymes. AHH-1 cell line only expresses CYP1A1, MCL-5 cells 
express all five CYP450 enzymes (detailed information for each cell line in Material and Method section).  TK6 
cells were used as a control as they are devoid of CYP450 enzymes. Therefore, all of these cell lines serve as a 
good tool to investigate the role of P450 enzymes in assessing the genotoxicity of chemicals that require 
metabolic activation. The stable expression system also furthers understanding of the process from metabolic 
activation of test compounds to the appearance of toxicological consequences entirely in the same intact cells. 
The study utilised the in vitro cytokinesis blocked micronucleus (CBMN) assay and hypoxanthine (guanine) 
phosphoribosyltransferase (H(G)PRT) assay in human cell lines to examine the induction of chromosomal 
damage and the frequency and spectra of point mutations, respectively. CYP450 enzymes levels and activity 
were also investigated in parallel through gene expression analysis and reporter assays.  
 
2. Materials and Methods 
2.1 Reagents 
HAT supplement (2×10
−4
M hypoxanthine, 8×10
−7
M aminopterin, and 3.5×10
−5
M thymidine), HT supplement 
(2×10
−4
M hypoxanthine and 3.5×10
−5
M thymidine) were purchased from Invitrogen (Paisley, UK), 6-
thioguanine, B[a]P, trypsin, hygromycin B, dimethyl sulfoxide (DMSO) and phosphate buffered saline (PBS) 
were purchased from Sigma (Gillingham, UK). N-Cyclohexyl-N-dodecylurea (NCND) was purchased from 
Calbiochem (EMD Chemicals Inc. US). Cytochalasin B was from Merck (Darmstadt, Germany). All powdered 
reagents were reconstituted according to manufacturer’s instructions. All chemical dilutions were freshly 
prepared from stock solutions and for each experiment new stock was prepared.  
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2.2 Cell Culture 
The present study utilised human male lymphoblastoid cell lines AHH-1, MCL-5 (ATCC, Middlesex, 
UK), TK6 and human hepatoma cell line HepG2 (ECACC, Salisbury, UK). The cell cycle doubling time for 
TK6 was 18h, for AHH-1 and MCL-5 22-24h, and 26-28h for HepG2. TK6 was isolated from WIL2, 
heterozygous at thymidine kinase (TK) locus and has a stable and wild-type p53 gene but minimal or no 
expression of CYP450 enzymes. 
  AHH-1 is a TK+/- with native CYP1A1 activity which was used for oxidative xenobiotic metabolism 
and was devoid of microsomal epoxide hydrolase [20]. It has +/- p53 gene. 
 MCL-5 cell line was a derivative of AHH-1 TK+/- that has been transfected with 4 cDNAs of the 
human CYP450s (carried on plasmids). These cDNAs include CYPA12, CYP2A6, CYP3A4 and CYP2E1 and 
microsomal epoxide hydrolase (mEH). MCL-5 has been shown to be more sensitive than AHH-1 TK+/- to the 
mutagenic properties of many pro-mutagens and pro-carcinogens and direct acting agents [21]. The plasmids 
were maintained in these cells through hygromycin (B) resistant genes. Both AHH-1 and MCL-5 harbour a 
heterozygous transition (C>T) p53 mutation at the codon 281/282 interface within exon 8, it retains the ability 
to undergo DNA damage–induced apoptosis and has been reported to express p53 which can be phosphorylated 
[22]. 
 HepG2 cells were isolated by Aden et al, (1997) from a primary hepatoblastome of an 11-year-old 
Argentine boy [23]. HepG2 have epithelial like morphology which resembles liver parenchymal cells and retain 
many of the specialized functions in culture such as secretion of major plasma proteins [24]. This cell line is a 
useful model of human liver cells and expresses many functional phase I and phase II xenobiotic metabolic 
enzymes [25].  
 All media used were purchased from GIBCO® (Life technologies, Paisley, UK) unless otherwise stated. 
The cell lines AHH-1, MCL-5, and TK6 were cultured in RPMI 1640 supplemented with 1% L-glutamine and 
10% donor horse serum (BD Gentest, Oxford, UK) in 80-cm
2
 flasks at 37°C, 5% CO2. In addition, MCL-5 cells 
were supplemented with hygromycin B at each passage to ensure plasmid retention. The cells were maintained 
at a concentration of 1-2 x 10
5 
cells/ml. HepG2 cell line was cultured in DMEM, supplemented with 10% foetal 
bovine serum and Pen/strep (penicilin and streptomycin [10,000U/ml]) and maintained at a concentration of 
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1.5-2 x 10
5 
cells/cm
2
. Each experiment was repeated three times and each replicate was independently produced 
on different days. 
 
2.3 Treatment with B[a]P 
For the CBMN assay all cell lines were treated with B[a]P for 4h or 24h followed by one cell cycle of 
cytochalasin B (3-6µg/ml depending on the cell type being used). The treatment regimes chosen (1-70µM) 
covered a range of doses, with the top concentration chosen as it produced less than 55+/-5% cytotoxicity, and 
thus any observed chromosome damage induction could not be contributed as a secondary effect of cytotoxicity 
[26]. For the HPRT assay, AHH-1 and MCL-5 cells were treated with B[a]P for 24h with 1, 2, 3, 4, 5 and 
10µM B[a]P. In 4h B[a]P treatment these cell lines were treated with 5, 10, 15, 20, 25, 30 and 50µM B[a]P. 
The highest concentration  of B[a]P used here caused a maximum of 40+/-5%  toxicity as adjusted by plating 
efficiency (PE). This is within the acceptable range for testing as described in the OECD guidelines 476 [27]. 
For the measurement of CYP1A1, CYP1B1, and CYP1A2 expressions and activities all cell lines were treated 
with LOELconcentration and concentration above LOEL of B[a]P for 24h, obtained as a result of CBMN assay. 
All the washing steps involved were done at room temperature and all centrifugation steps performed at (300 x 
g) for 5min. 
 
2.4 Cytotoxicity assessment using relative population doubling 
The cytotoxicity of B[a]P dissolved in DMSO was determined by relative population doubling (RPD) in 
the absence of cytochalasin B following the procedure described by Brüsehafer et al. [28] with a few 
modifications. HepG2 cells were seeded at 1.2x10
5 
cells/cm
2
 at 37ºC, 5% CO2, cells from each treatment flask 
were counted (control treatment) with the Beckman coulter counter (Z1 Coulter Particle Counter, Beckman, 
UK) and incubated for 24h. AHH-1, MCL-5 and TK6 cells were seeded at 1x10
5
 cells/ml for 24h and cells 
were counted (control treatment) from each flask 1h before treatment. All four cell lines were again counted at 
the cell harvest stage (treated cultures). 
  
2.5 The Cytokinesis blocked micronucleus assay 
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Micronuclei (MN) frequency was utilized to assess the in vitro level of chromosomal damage induction. 
The assay was performed as previously described by Seager et al. [29] with a few modifications. AHH-1, 
MCL-5 and TK6 (10ml) suspensions of cells at 1 x 10
5 
cells/ml and HepG2 at 1.2 x 10
5 
cells/cm
2
, were seeded 
for 24h at 37°C, 5% CO2. Flasks were treated with appropriately diluted B[a]P for 4h or 24h, after which AHH-
1, MCL-5 and TK6 cells were centrifuged (pipetted off the medium from HepG2 flasks), washed twice with 
RPMI 1640 (without supplement), and re-suspended in 10ml fresh media containing 6µg/ml cytochalasin B for 
one cell cycle (22h for AHH-1 and MCL-5 and 26h for HepG2), 3µg/ml for TK6 (18h). Treated cells (AHH-1, 
MCL-5 and TK6) were washed twice by centrifugation with PBS while HepG2 cells were washed twice and 
then trypsinised. Slides were prepared for the Metafer 4 software, version 3.8.5 (MetaSystems, Altlussheim, 
Germany) as described by Seager et al. [30]. A minimum of 3333 binucleated cells were scored per replicate, 
and each treatment was performed in triplicate (an average of 10,000 binucleates per treatment).  
 
2.6 The hypoxanthine phosphoribosyltransferase assay 
The in vitro HPRT assay was used to study the gene mutations at HPRT locus.To reduce the background 
mutants, AHH-1 and MCL-5 cells were cultured for 3 days in RPMI 1640 containing 50X HAT media, which 
is lethal to cells that harbour mutations at the HPRT. Subsequently, the cells were transferred to media 
containing 50X HT media for 24h and then grown in normal media for two days to achieve sufficient cell 
number for treatments. 
 The assay was performed as previously described by Doak et al. [31], with the following modifications: 
AHH-1and MCL-5 cell suspensions (10 ml), at 4 x 10
5
 cells/ml, were exposed to the test chemical in 80-cm
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flasks at the appropriate concentration for 4h or 24h at 37°C, 5% CO2. It was noted by using the two-tailed t-
test that the mutant frequency (MF) of the solvent control (DMSO) is non-significantly different from that of 
the untreated control, with MF being 0.18×10
−5
 ± 0.03 (mean ± SE) and 0.26×10
−5
 ± 0.03, respectively for 
AHH-1 and 2.2×10
−5
 ± 0.15 (mean ± SE) and 2.39×10
−5
 ± 0.13, respectively for MCL-5. 
 
2.7 Clonal expansion of mutants 
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Solvent control and 10μM B[a]P treated HPRT mutant colonies were transferred to 24-well plates 
containing 2ml growth medium per well and grown for 5 days at 37°C, 5% CO2, after which 300µl of the 
individual colony was carefully extracted and mixed with 1.5 ml RNA protect (1:5, Sigma, UK) and stored at -
20°C for RNA extraction.  
 
 
 
2.8 RNA extraction and cDNA amplification 
Total cellular RNA was extracted using the RNeasy mini kit (Qiagen, West Sussex, UK) with DNase 
treatment and RETROscript
®
 kit (Ambion, Sussex, UK) was used for cDNA synthesis, according to the 
manufacturer’s instructions. End-point PCR of cDNA was performed by using a GoTaq® Flexi DNA 
Polymerase kit (Promega, Southampton, UK), on an iCycler (Bio-Rad, Hemel Hemstead, UK).  The β-actin 
primers (forward: 5ʹ-GATGGCCACGGCTGCTTC-3ʹ, reverse: 5ʹ- TGCCTCAGGGCAGCGGAA-3ʹ with 
product size 100bp) which clarify the cDNA reaction were synthesized by MWG Eurofins (Germany). The 
HPRT primers used to amplify the HPRT cDNA were previously mentioned by [32]. Separate reactions were 
established for each primer pair. Approximately 1µg RNA was used for cDNA synthesis and PCR in a reaction 
volume of 50µl, containing 10µl of 5x colorless GoTaq
®
 Flexi Buffer, 4µl MgCl2 solution, 1µl of dNTP mix, 
1µl GoTaq
®
 DNA polymerase, and 1µl of each primer at a final concentration of 0.2µM and 30.7µl of 
Nuclease-free water. The following PCR reaction protocol was used: initially cDNA production occurred for 
one cycle at 44°C for 60min followed by 90°C for 10min. Subsequently, PCR was initiated for 31 cycles of 
93°C for 2min, 93ºC for 10s, 52.6ºC for 20s, 72ºC for 10s and prior to storage at 4
o
C until downstream analysis 
occurred. Reactions were performed in triplicate, and PCR products were visualized using DNA 
polyacrylamide gel electrophoresis on 6% polyacrylamide gel followed by 0.1% silver nitrate staining.  
 
2.9 Sample preparation for sequencing 
PCR products were purified by using Qiagen PCR purification kit
®
 (Sussex, UK) according to the 
manufacturer’s instructions. Finally, 20µl of each sample was sent to Genome enterprise Limited for forward 
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and reverse sequencing. Mutations were identified using Mutation Surveyor version 3.0 (Soft genetics, State 
College, PA). Any mutation found was confirmed by repeat processing. 
 
2.10 Construction of mutation spectra 
Mutation spectra were constructed using iMARS sofware [33]. 
 
 
 2.11 Expression of CYP450 enzymes using quantitative real-time PCR 
The expression of CYP1A1, CYP1B1, and CYP1A2 mRNA in human cell lines AHH-1, MCL-5, TK6 
and HepG2 was evaluated qualitatively using real-time reverse transcriptase-PCR. MCL-5, AHH-1 and TK6 
cells were seeded at a density of 1x10
5 
cells/ml and HepG2 at 1.2x10
5 
cells/cm
2
. After 24h incubation cells were 
exposed for 24h with B[a]P. Following the exposure period cells were washed twice and the RNA was 
extracted as mentioned previously. The purified RNA samples were reverse transcribed using the QuantiTect
®
 
Reverse Transcription Kit from Qiagen (Sussex, UK) according to manufacturer’s instructions. All the primers 
were synthesized by Sigma-Aldrich (UK) and the oligonucleotide sequence and product size for each primer 
were as follows; CYP1A1- forward, 5ʹ-ATCCTTGTGATCCCAGGCTCC-3ʹ, reverse, 5ʹ-
TAGGGATCTTGGAGGTGGCTGA-3ʹ with product size 76bp, CYP1A2- forward, 5ʹ- 
CCAACGTCATTGGTGCCATG-3ʹ, reverse, 5ʹ-GTGATGTCCCGGACACTGTTC-3ʹ with product size 262bp 
and CYP1B1-forward,5ʹ-TCCTCCTCTTCACCAGGTATCC-3ʹ, reverse, 5ʹ- TGGTCACCCATACAAGGCAG-
3ʹ with product size 97bp. Real-time PCR was then performed on an iCycler iQ5 Thermal Cycler (Bio-Rad, 
Hertfordshire, UK) using the QuantiFast SYBR Green PCR Kit (Qiagen). The resultant data were analysed by 
the standard curve method and genes of interest were normalized against β-actin. 
 
2.12 Measurement of CYP450 activity 
The CYP450 activity was determined using the P450-Glo 1A1 assay, 1B1 assay and 1A2 assay kits 
(Promega, USA), according to the manufacturer’s instructions. MCL-5, AHH-1 and TK6 cells were seeded at a 
density of 1x10
5 
cells/ml and HepG2 at 1.2x10
5 
cells/cm
2
. After 24h incubation cells were exposed for 24h with 
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B[a]P and washed twice with PBS. For the measurement of CYP1A1 and 1B1, the cells were maintained at 
5x10
5
 cells/ml concentration in culture medium. Medium (50µl) containing 5mM luminogenic CYP1A1-CEE 
was added in 50µl cell suspension in 96 well-plate and incubated at 37°C for 3h. CYP1A2 activity was 
measured by adding the 50µl diluted Luciferin-1A2 in PBS containing 3mM salicylamide to inhibit the phase II 
conjugation of the CYP product from CYP1A2-Luciferin 1A2, into 50µl cell suspension and incubated for 
30min. Luceferin detection reagent with D-cystene was reconstituted as directed by instructions for use. An 
equal volume of Luciferin Detection Reagents were added at the end of the incubation period to the cells to 
measure the activity after 10min on FLOURstar OPTIMA (BMG Lab technologies Ltd., UK). CYP450 
activities were calculated by subtracting the background and normalizing to the seeded cell number. 
 
2.13 Statistical analysis 
For the cytotoxicity data error bars, are represented as standard errors (SEs) of the mean. For 
genotoxicity data a one-way ANOVA approach, followed by two-tailed Dunnett’s post hoc test, was used to 
determine if any of the treatment doses were significantly different from the zero dose (p<0.05), except in the 
HPRT assay the control and solvent control were analysed using t-test. The hockey stick modelling of apparent 
thresholds was carried out using software, kindly provided by Lutz and Lutz [34] and implemented in the R 
package. A one-way ANOVA approach, followed by two-tailed Dunnett’s post hoc test, was used to determine 
the basal and induced expression of CYP450 enzymes after B[a]P treatments. 
 
3. Results 
The present study explored the contribution of metabolic capacity on the genotoxic dose responses 
obtained for B[a]P. The cell lines selected to assess the induction of MN and HPRT mutations by B[a]P have 
varying metabolic competency.  
 
3.1 The CBMN assay to determine B[a]P induced genotoxicity 
The cell lines TK6, AHH-1, MCL-5 and HepG2 were tested for their ability to metabolise B[a]P into 
toxic/genotoxic metabolites after 24h exposure, as measured by cell viability and induced DNA damage. B[a]P 
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did not show any significant cytotoxic or genotoxic effects in the TK6 cell line at any of the doses tested 1-
70µM (Figure 1A). In contrast to TK6, AHH-1 cells showed a slight increase in cytotoxicity, (55+5% 
cytotoxicity was not achieved even at highest concentration of 70µM. However, a gradual increase in genotoxic 
dose response was observed in AHH-1 cells and the frequency of MN (%MN/BN) was significantly increased 
at a B[a]P concentration of 4µM (p<0.01) which was the LOEL concentration (Figure 1B). In comparison, the 
more metabolically competent cell lines showed a greater sensitivity to B[a]P with >55% cytotoxicity observed 
in MCL-5 and HepG2 cells at 25µM and 5µM concentrations respectively (Figures 1C and 1D). Due to the 
higher cytotoxicity of B[a]P in HepG2 cells, studies were restricted to a maximum concentration of 10μM of 
B[a]P. Increases in DNA damage levels (%MN/BN) were observed in both MCL-5 and HepG2 cells after 24h 
B[a]P treatment. The LOEL concentration was 3µM (p<0.05) for both cell lines as illustrated in Figure 1C, 1D. 
The Hockey-stick model analysis revealed a linear dose-response for MN induction after B[a]P in AHH-1, 
MCL-5 and HepG2 cell lines.  
 In order to explore the effect of a shorter exposure time on B[a]P’s genotoxicity a 4h exposure CBMN 
assay was also performed. AHH-1, MCL-5 and HepG2 cells were treated with B[a]P using a dose range of 10-
70µM for 4h. TK6 was omitted as negative results were seen at 24h. Similar to the 24h B[a]P treatment, AHH-
1 cells had low cytotoxicity (<55% at the highest concentration of 70µM B[a]P), but significant cytotoxicity 
(>55%) was observed in both MCL-5 and HepG2 cells at 60µM and 10µM B[a]P, respectively (Figure 2). In 
contrast to 24h exposure, no elevation in MN frequency was observed in AHH-1 following B[a]P treatment 
(Figure 2A). A LOEL for MN was observed in MCL-5 cells at 40µM (p<0.05) B[a]P (Figure 2B), compared to 
3µM with 24h exposure above.  An increasing genotoxic response was also observed in HepG2 cells with a 
significant increase in the frequency of MN/BN cells (a LOEL) observed at 20µM (p<0.05), compared to 3µM 
with 24h exposure above. Hockey-stick statistical modelling  rejected the linear dose-response and supported 
the threshold model in MCL-5 cells after 4h exposure and confirmed an estimated inflection point (IP) at 
25.46µM (p<0.002) with lower confidence interval (CI) of 14.60µM with B[a]P.  The dose response curve for 
B[a]P in HepG2 cell line was however linear. 
 
3.2 Role of microsomal epoxide hydrolase in  micronuclei  induction  
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To confirm the importance of mEH in inducing an increased genotoxic potential and potency of B[a]P, 
as shown in MCL-5 cells specifically, N-Cyclohexyl-N’-dodecylurea (NCND), an effective inhibitor for mEH 
[37] was used. When MCL-5 cells were pre-treated for 2h with NCND (dose 170nM) and then exposed to 
70µM B[a]P for 24h MN induction decreased (1.6-fold) and cytotoxicity reduced from 84% to 25% as 
compared to cells without pre-treatment.  
 
 
3.3 Mutation frequency at HPRT loci for B[a]P  
The HPRT assay was also performed in both AHH-1 and MCL-5 cells in order to study the mutagenic 
effect of 4h and 24h exposure of B[a]P. The B[a]P concentrations selected for this study were low 
concentrations including the LOEL dose that produced the first significant increase in the CBMN assay. TK6 
cells were not used because they did not show any genotoxicity with B[a]P, while HepG2 cells are less 
amenable to the HPRT assay. The AHH-1 cell viability did not vary significantly after treatment with B[a]P 
and the background mutation frequency (MF) of AHH-1 cells was found to be 0.18 x10
-5 
HPRT mutants. 
Despite low toxicity levels, AHH-1 cells showed increased MF with increasing B[a]P concentration (with 24h 
exposure). MF was significantly increased from 0.18 x10
-5 
in control to 3.14 x10
-5
 at 4μM (p<0.05) and 5.52 
x10
-5
 at the top concentration of 10μM (p<0.001) (Figure 4A). The LOEL detected was 4µM which 
corresponded with the CBMN assay. 
 A small reduction in cell viability was observed in  MCL-5 cells treated with 3µM B[a]P for 24h, yet 
cell viability was still 74.65% (approximately 25% toxicity) at the top concentration of 10µM. A linear increase 
in MF was observed over the 1-5μM concentration range, which was followed by a sharp increase in MF at the 
10μM concentration. MF was significantly increased from 2.20 x10-5 in untreated control cells to 22.96 x10-5 at 
2µM (p<0.01) and 99.3 x 10
-5
 at the highest cencentration of 10µM (p<0.001). The LOEL observed was 2µM 
(less than that of the corresponding MN assay) (Figure 4A). MCL-5 was observed to be far more sensitive than 
AHH-1 in term of mutation induction. Hockey stick modelling revealed that B[a]P exhibited a linear dose-
response in both AHH-1 and MCL-5 cells after 24h exposure and no threshold dose was found.  
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 There was a non-significant difference in % cell viability observed in both MCL-5 and AHH-1 cell lines 
when exposed to B[a]P for a shorter time of 4h. The MF was not increased in AHH-1 cells at all but it was 
significantly elevated with increasing concentration in MCL-5 cell line and the LOEL was found to be 10μM 
(p<0.01) with a linear dose response (Figure 4B), compared to a LOEL at 2µM with 24h exposure. 
 
3.4 Spontaneous and B[a]P-induced Mutations in AHH-1 and MCL-5 HPRT mutants 
A clear difference was seen in the patterns of the HPRT mutations from AHH-1 (Table I, 
Supplementary Table S1A) and MCL-5 (Table I, Supplementary Table S1B) solvent control and B[a]P treated 
mutants.  
 In the AHH-1 solvent control, a total of 14 spontaneous mutations were observed with deletions (93%) 
being the most dominant mutations (Figure 5A). The remaining 7% of mutations represented a single tandem 
mutation (TG285/6AT) (Supplementary Table S1A). B[a]P treated AHH-1 mutants showed predominantly 
(61%) point mutations, out of which 44.4% were G>T transversions. Other mutations such as CT transitions 
(11%), insertions (5.5%), and deletions (33%) were also observed (Table I, Figure 5B). There were no 
transitions or transversions mutations in AHH-1 control cells and the ratio of transitions;transversions was 2:9 
in B[a]P- treated cells. In the MCL-5 solvent mutants, 25 mutations were analysed and the mutational spectrum 
constituted 40% deletions, 36% transversions and 12% transitions mutations and 12% TG285/6AT tandem 
mutations (same mutation as AHH-1) were also observed (Table I, Figure 5C). B[a]P induced mutants 
predominantly contained point mutations (80%). Among all the point mutations, the proportion of G>T 
transversion mutations was higher (72% as compared to 4% transitions). The remaining 20% mutations 
detected were deletions (Table I, Figure 5D). The transitions:transversions ratio in control cells was 1:3 but for 
B[a]P-induced mutations it was 1:19. Most of the B[a]P induced mutations in AHH-1 and MCL-5 mutants 
were observed at exons 2 and 3 (Supplementary Table S1A and 1B). It was also noted that all G>T point 
mutations found in both MCL-5 and AHH-1 mutants were all on the non-transcribed strand. CYP expression 
levels to explain cell lines specificity 
In order to explore if the expression levels of the key CYP450’s explained the cellular differences 
observed in cytotoxicity/genotoxicity after B[a]P exposure, we studied mRNA expression of key CYP450’s in 
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each cell line before and after B[a]P treatment. There was a difference in both the basal and induced expression 
of CYP1A1, CYP1B1 and CYP1A2 for all cell lines. Basal expression of CYP1A1 in MCL-5, AHH-1 and 
HepG2 cells are shown in Figure 6. CYP1B1 and CYP1A2 were found only in MCL-5 and HepG2 (Figure 6b 
and c). Results from Real-time PCR showed an increase in expression of various CYPs with increasing 
concentrations of B[a]P, in both MCL-5 and HepG2 cell lines as compared to the untreated control. After 24h 
B[a]P treatment at the corresponding LOEL concentration, the induction of CYP1A1  increased 29.2-fold 
(p<0.001) in MCL-5 and 16.81-fold (p<0.01) in HepG2  (Figure 6A). The change in CYP1B1 expression, after 
24h B[a]P exposure at the corresponding LOEL concentration was 10.52-fold (p<0.05) in MCL-5, but no effect 
was found in HepG2 (Figure 6B). B[a]P-induced CYP1A2 expression was elevated by 4.43-fold (p<0.001) and 
18.95-fold (p<0.05) in the MCL-5 and HepG2 cell lines respectively (Figure 6C).  
 
 
3.5 CYP activity in different cell lines 
CYP1A1, 1B1 and 1A2 enzyme activities in MCL-5, AHH-1, TK6 and HepG2 cultures were also 
assessed after 24h B[a]P exposure (Figure 7) using enzyme activity assays.  CYP1A1 activity was significantly 
higher in MCL-5 than other cell lines, reflecting the mRNA results above. CYP1A1 activity increased 
significantly (p<0.01) with increase in concentration of B[a]P in all cell lines except TK6 (Figure 7A). 
CYP1B1 activity was significantly (p<0.05) high in both MCL-5 and HepG2 cells but was minimal in AHH-1 
and TK6 (Figure 7B). CYP1A2 activity was highly significant (p<0.001) in HepG2 cells at all treatments, 
reflecting the mRNA data above, with MCL-5 cells also showing activity. AHH-1 and TK6 cell did not show 
an increase in CYP1A2 activity at any treatment (Figure 7C). 
 
4. Discussion 
This study assessed the interplay between treatment and metabolic competence in determining 
genotoxic hazard in vitro. This is an important aspect in both hazard identification and risk assessment for 
chemicals that require metabolic activation. In the former, the most sensitive test is usually used to increase the 
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chances of detecting potential pro-mutagens, but in the latter, it is important to recognise the appropriateness of 
the system overall, to better reflect human risks. 
 
4.1 Effect of differential metabolic competency on micronucleus frequencies after 4h and 24h exposure 
The micronucleus assay data and gene expression and activity analysis of CYP1A1, CYP1B1 and 
CYP1A2 in the different cell lines showed a clear connection and positive correlation between CYP450 
metabolic capacity and B[a]P’s genotoxicity. Active AhR is the necessary requirement for the transcriptional 
activation of CYP1A1, 1A2 and 1B1 and thus conversion of Ba]P into genotoxic metabolites.  Indeed, in vivo 
studies by Shimizu et al. [38] have confirmed that upon B[a]P  administration, tumour formation was only 
observed in AhR (+/+) and (+/-) mice but not in AhR (-/-) mice. Similarly, the more metabolically competent 
cell lines MCL-5 and HepG2, which express AhR,  [39, 40] showed greater genotoxicity in response to lower 
concentrations of B[a]P than AHH-1 and TK6 cell lines. CYP1A1 and CYP1B1 mRNA expression levels and 
CYP450 activity in B[a]P treated cells was substantially higher in MCL-5 cells and this correlated with the 
highest frequency of B[a]P induced micronuclei. Similarly, cells with lower basal or induced expression of 
CYP1A1 or other P450 enzymes showed little (AHH-1 cells) or no (TK6 cells) cytotoxic or genotoxic effect of 
B[a]P. Johnson et al. [41] also observed higher micronucleus frequencies in MCL-5 cells as compared to AHH-
1 cell line for Azo dyes (Sudan 1 and Para red) which require metabolic activation. In the HepG2 cell line, an 
increase in B[a]P dose, resulted in a higher MN/BN frequency and an increase in CYP1A2 activity and 
expression, thus highlighting the role of CYP1A2 in B[a]P induced genotoxicity. Further, the treatment at 
which a significant increase in genotoxicity was first observed was much lower in MCL-5 and HepG2 cells 
than AHH-1 (Figure 1). The results obtained with AHH-1 cells support the earlier studies of Penman et al. [20] 
who also observed that lower levels of CYP1A1 and an absence of mEH made the AHH-1 cell line less 
metabolicaly competent. The link between mEH and B[a]P metabolism was observed when MCL-5 cells 
treated with NCND (an effective inhibitor for mEH) [37]. These findings indicate that B[a]P conversion to its 
mutagenic intermediates in cells devoid of mEH and with lower CYP1A1 levels, is slow and thus requires more 
time to convert similar quantities of B[a]P into its genotoxic metabolites . 
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Dose response thresholds for genotoxins can be used to assist the prediction of a safe exposure level. 
The theory behind genotoxic thresholds suggests that a compound will not produce an observable increase in 
DNA mutation below a critical exposure level and therefore, this does not increase the risk for the induction of 
cancer or congenital abnormalities.  In this study, presence of a linear  dose-response for MN at 24h exposure to 
B[a]P for all the metabolically competent cell lines may be explained by the potent formation of stable DNA 
adducts at N2-guanosine residues [42] which if left unrepaired, can block replication and transcription. Even a 
single BPDE-DNA adduct can effectively block expression of a reporter gene [43] and has been linked to 
mutations in multiple oncogenes including p53 and Kras, causing severe damage to cell integrity, function and 
replication [44]. It is important to note however, that this linearity is intrinsically linked to metabolic capacity. 
It would be interesting to further study the dose responses to B[a]P in target tissues (e.g. lung) with intrinsic 
levels of metabolism likely to be far less than the MCL-5 and HepG2 cells here. 
 
4.2 Comparison of the chromosome damage LOEL to the mutational LOEL 
MCL-5 cells were more sensitive than AHH-1 cells to B[a]P-induced genotoxicity in general, which 
was likely due to the higher CYP450 enzyme expression in MCL-5 (Figure 6). However, the lesions that cause 
gene mutations (HPRT here) may be different from those that cause chromosomal breaks (micronuclei). 
Micronucleus formation occurs after multiple events including strand breaks during mitotic or failed DNA 
repair, whereas the HPRT assay can detect a single modification in the DNA mis-replicated during DNA 
synthesis. This increased assay sensitivity is reflected in the LOELs for HPRT mutations tending to be lower 
than those of MN induction. The LOELs in the CBMN assay after 24h B[a]P exposure were 3µM and 4µM in 
MCL-5 and AHH-1 cell lines respectively, whereas in the HPRT assay it shifted to 2µM in the MCL-5 cell line 
and remain unchanged in AHH-1. In the case of 4h B[a]P exposure, the LOEL was 40µM in CBMN assay and 
was 10µM in HPRT assay for MCL-5 cells.  
 
4.3 Mutation spectra 
HPRT mRNA was extracted and used to establish the spontaneous and induced mutation patterns in 
AHH-1 and MCL-5 cell lines. The B[a]P induced G to T mutations were all found on the non-transcribed 
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strand thus suggesting efficient transcription coupled repair of B[a]P DNA adducts on the transcribed strand. 
Mutation spectra of solvent control for both cell lines, AHH-1 (Figure 5A) and MCL-5 (Figure 5C) mainly 
consist of deletions whereas B[a]P treated cell lines mutation spectra shows a range of mutations (Figures 5B 
and D), mostly involving G to T transversions (implicating N2-dG adduct) supporting earlier reports where 
frequent G to T transversions were observed in the smoking associated  mutational spectra of human lung 
cancer [45, 46]. Pfiefer et al. [46] also reported a high incidence of G to T transversions in p53 in lung samples 
as compared to larynx and the oral cavity of smoking associated cancers. Indeed, PAHs (such as B[a]P) present 
in smoke are believed to be responsible for the link between smoking and lung cancer. B[a]P from cigarette 
smoke has been linked with lung cancer, and studies [45] have reported distribution of BPDE adducts along 
exons of the TP53 gene in BPDE-treated HeLa cells and bronchial epithelial cells. This study further showed 
adduct formation at guanine positions in codons 157, 248, and 273, which are believed to be major mutational 
hotspots in human lung cancer. 
The strengths of this study include the comparison of cytotoxicity/genotoxicity in four cell lines 
coupling two genotoxic endpoints to the expression levels and activity of key CYP450’s. The study evidences 
crucial links between metabolic activity, exposure time and genotoxic hazard posed by B[a]P. Weaknesses of 
the study include the use of secondary endpoints (cytotoxicity/genotoxicity) to infer metabolic activation of 
B[a]P as opposed to DNA adduct measurements and also the sole focus on phase I metabolism activating B[a]P 
without consideration for phase II detoxification. 
 In conclusion, this study shows that TK6 cells have negligible metabolic ability to metabolise B[a]P, 
and showed  no cyotoxicity nor genotoxicity, confirming that B[a]P is non-toxic without metabolic conversion. 
We further show that CYP450 enzymes and  mEH play an important role in the metabolic activation of B[a]P 
and the combined presence of CYP1A1, CYP1A2 and mEH caused MCL-5 and HepG2 cells to acquire more 
micronuclei and HPRT mutations compared to AHH-1 cells. The present study, thus emphasises the importance 
of considering the metabolic efficiency of in vitro cell systems when assessing dose responses to pro-
carcinogens. We also suggest that metabolically competent cell lines offer an attractive alternative to rat liver 
S9 which may not necessarily be reflective of human liver physiology. 
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Type of Mutations 
AHH-1 solvent 
control 
AHH-1 
B[a]P treated 
MCL-5 solvent 
control 
MCL-5 B[a]P 
treated 
Point mutations 0 11 12 20 
Transitions         
C > T   2 (11%) 3 (12%) 1 (4%) 
Transversions         
G > C   1 (5.5%) 5 (20%) 1 (4%) 
C > G     2 (8%)   
G > T   8 (44.4) 2 (8%) 18 (72%) 
Tandem 
mutations 
1 (7%)   3 (12%)   
Deletions 13 (93%) 6 (33%) 10 (40%) 5 (20%) 
Insersions   1 (5.5%)     
 
TABLE I. Percentages and Types of Spontaneous and Benzo-a-pyrene (B[a]P)-induced mutations (10μM) dose 
at the HPRT locus in  AHH-1 and MCL-5 mutants after 24h exposure. Letters stands for bases; C (cytosine), T 
(thymine), G (guanine).   
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Legands 
Fig. 1. Data of 24h exposure: Cytotoxicity (Relative population doubling (RPD) (%)) and micronucleus 
frequency (%MN/BN, micronuclei/binuclei) induced by increasing concentrations of Benzo[a]pyrene (B[a]P) 
in TK6, AHH-1, MCL-5 and HepG2 cell lines. The Lutz model outcome for micronucleus data, if  linear, is 
labelled as “Linear”. Line graphs show RPD and bars show %MN/BN. *, ** and *** indicates statistically 
significant results (p<0.05, 0.01 and 0.001 respectively) compared with that of the control samples. All data 
points represents the mean of three replicates. Error bars are standard error (SE). 
 
Fig. 2. Data of 4h exposure: Cytotoxicity (%RPD) and micronucleus frequency (%MN/BN) induced by 
increasing concentrations of B[a]P in AHH-1, MCL-5 and HepG2 cell lines. The Lutz model outcome for 
micronucleus data, if  linear, is labelled as “Linear”. Line graphs show RPD and bars show %MN/BN.  *, ** 
and *** indicates statistically significant results (p<0.05, 0.01 and 0.001 respectively) compared with that of 
the control samples. All data points represents the mean of three replicates. Error bars are SE. 
 
Fig.  3. Effect of NCND, epoxide hydrolase inhibitor, on Cytotoxicity (%RPD) and micronucleus frequency 
(%MN/BN) in MCL-5 cells after 24h exposure to 70µM B[a]P. All data points represents the mean of three 
replicates. Error bars are SE. 
 
Fig.  4. Gene mutation frequency (HPRT, bars) and Cell viability (%RPD, lines) induced by B[a]P. Dose 
response relationships at the HPRT gene in response to B[a]P for 4h (A) and 24h (B). All data points represents 
the mean of three replicates. Error bars are SE. 
 
Fig. 5. Distribution of spontaneous (A and C) and Benzo[a]pyrene-induced (B and D) mutations in the HPRT 
gene in AHH-1 and MCL-5 mutants. Each base and its number on the HPRT sequence are presented on the x-
axis. The number of mutations is portrayed on the y-axis. Each base alteration is colour coded where the letter 
25 
 
X stands for the 4 bases; A (argenine), C (cytosine), G (guanine) or T (thymine) determined by the position on 
the sequence. Numbers in the rectangular boxes represent the hotspots on exons. 
 
Fig.  6. Basal and induced expression of (A) CYP1A1, (B) CYP1B1 and (C) CYP1A2 genes in the 4 cell lines 
after 24h exposure to B[a]P. The numbers 1 and 2 refer to the NOEL and LOEL dose for each cell line (for MN 
induction). (0) Untreated control, MCL-5 (1) 3μM, (2) 4μM; AHH-1 (1) 4μM, (2) 5μM; TK6 (1) 5μM, (2) 
10μM; HepG2 (1) 3μM, (2) 4μM. Levels of CYP1A1, 1B1 and 1A2 mRNA were assessed by quantitative real-
time PCR (A, B and C). Values were normalized using housekeeping gene β-actin and represent the mean fold 
change from vehicle control levels at each point for each cell line. After reverse transcriptase PCR, the samples 
were run on acrylamide gel and silver stained. The bands represent the expressions of CYP1A1 (a), CYP1B1 (b) 
and CYP1A2 (c) in cell lines at different doses. 
 
Fig. 7. Basal and induced phase I CYP1A1 (A), CYP1B1 (B) and CYP1A2 (C) enzyme activities (expressed as 
relative luminescence units [RLU]/cell number per well) in different cell lines after 24h exposure to B[a]P. (0) 
Untreated control, MCL-5- (1) 3μM, (2) 4μM; AHH-1- (1) 4μM, (2) 5μM; TK6- (1) 5μM, (2) 10μM; HepG2- 
(1) 3μM, (2) 4μM. ** and *** indicates statistically significant results (p<0.01 and 0.001 respectively) 
compared with that of the control samples. All data points represents the mean of three replicates. Error bars are 
SE. 







